After the executive order, after the vouchers, after half a century of prohibition finally started to give: a map of how legal psychedelic medicine actually reaches America, who provides it, and how patients find their way through.
By the authority vested in the executive, and in recognition of an unprecedented mental-health crisis among the men and women who served this nation — the following directives are hereby issued for the regulated, accelerated, and dignified entry of psychedelic medicines into the legal therapeutic frontier of the United States.
That the Department of Veterans Affairs has documented suicide, post-traumatic stress, traumatic brain injury, and treatment-resistant depression at rates incompatible with the continued status quo of psychiatric care. That a body of peer-reviewed clinical research — at Johns Hopkins, Stanford, NYU, Imperial College London, and within the VA's own laboratories — now establishes the therapeutic credibility of compounds long held in Schedule I.
That on this date, the Food and Drug Administration has issued Priority Review Vouchers to Compass Pathways, the Usona Institute, and Transcend Therapeutics — designating their psilocybin and methylone programs as breakthrough therapies of national interest.
The Department of Veterans Affairs shall expand and accelerate clinical research into psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT for the treatment of PTSD, depression, and traumatic brain injury — and shall remove administrative barriers to veteran enrollment in trials currently underway at Stanford, NYU Langone, and partnered VA medical centers.
The Drug Enforcement Administration shall, in coordination with the FDA and HHS, prepare scheduling reviews for compounds receiving breakthrough therapy designation — to ensure that approved medicines do not remain under Schedule I in contradiction of their established medical utility.
The State Department and Department of Health and Human Services shall coordinate with international partners on ethical, regulated cross-border treatment access — particularly for ibogaine therapies presently delivered in licensed clinics outside the United States.
This order does not legalize. It does not decriminalize. It does not endorse recreational use. It opens a door — through which trained clinicians, credentialed researchers, qualifying patients, and the veterans of this nation may walk toward medicines that have, in the careful hands of science, demonstrated the capacity to relieve suffering that nothing else has touched.
The era of categorical prohibition for medicines of established therapeutic value is hereby declared concluded.
A proprietary crystalline synthetic psilocybin, given as a single 25 mg dose with psychological support built around it. It's the largest Phase 3 psilocybin program ever run, and the one most likely to become the first regulated psilocybin medicine in the country.
The nonprofit answer to commercial psychedelic development. Usona's Phase 3 program for major depressive disorder is chasing approval with a stated goal of keeping psilocybin affordable, at a price that isn't set by what venture investors need to make back.
Methylone, MDMA's slightly older, shorter-acting structural cousin, moving forward as TSND-201 for PTSD. After the FDA turned down Lykos's MDMA-AT in 2024, methylone's pharmacology and tidier trial design make it the most credible entactogen still on a path to approval.
The most established ibogaine clinic anywhere, cardiac-monitored and hospital-credentialed, and home to the Beond Service Program, which delivers ibogaine therapy free to qualifying veterans and first responders. An Austin expansion is in the works, and the waitlist currently runs into the fall.
A bipartisan appropriation pushed through the Texas legislature by veteran advocates, setting up the first framework for FDA-aligned ibogaine research on US soil. For the next decade, this is where the politics of legal ibogaine will center.
A Nature Medicine study of 30 special-operations veterans with TBI and PTSD who were treated with ibogaine in Mexico, then followed at Stanford. The results: big drops in PTSD, depression, and anxiety, plus meaningful gains on TBI-related cognition. It's the single most cited piece of clinical evidence in the case for giving veterans ibogaine.
Positioned more toward clinical research than Beond: Ambio publishes outcome data, works with US researchers, and serves a population that overlaps with Beond's without being the same. Another name worth knowing in the ibogaine chapter.
The dominant at-home ketamine therapy provider in the United States. Telehealth-prescribed, clinician-monitored, sublingual ketamine delivered by mail with structured psychological support. Six-session protocols and ongoing maintenance plans available.
The S-enantiomer of ketamine, given as a nasal spray under in-clinic supervision by REMS-certified providers. It's approved for treatment-resistant depression and for acute suicidal thinking in major depression. Insurance is increasingly covering it, which is what makes Spravato such a big part of the access conversation.
Joyous goes after a different crowd with $129-a-month daily-microdose protocols, which is a genuinely different model. Innerwell and Better U sit somewhere in between. Think of them as honest alternatives: different prices, different protocols, different patients.
The first U.S. state to license and regulate the supervised therapeutic use of psilocybin. Measure 109, passed in 2020 and operational by 2023, established the licensing structure for facilitators, service centers, manufacturers, and laboratories. Adult, non-medical use under licensed supervision.
A broader framework than Oregon's. It covers psilocybin and a planned phase-in of DMT, ibogaine, and mescaline (peyote left out, out of respect for Indigenous communities), with personal-use protections sitting alongside the licensed-facilitator model. It's the most ambitious state psychedelic law currently on the books.
A growing list of state legislatures with active psilocybin or natural-medicine bills, decriminalization measures, or study commissions on therapeutic access. The post-EO climate is speeding all of it up. We'll track each one as it moves, and flag the ballot initiatives worth watching.
After the 2024 rejection, Lykos changed up its leadership, took the advisory committee's criticisms on board, and is running more trials with the design fixes regulators asked for. The road ahead is longer than anyone wanted. The goal hasn't moved.
A new wave of MDMA-class developers learning from what happened to Lykos: tighter trial design, real expectancy controls, and a closer relationship with regulators starting in Phase 1. Whether or not Lykos gets there first, this is the next credible MDMA-class door.
Worth saying again here: the most credible near-term path to a regulated MDMA-class PTSD medicine may not be MDMA at all, but methylone, its close structural cousin, shorter-acting, moving forward as TSND-201 under a priority voucher. The MDMA pipeline didn't collapse so much as split in two.
The directory will launch in the first ninety days of the Volume III rollout — seeded with free listings for trusted providers across all six categories, with paid tiering activated as the listing base matures. Provider applications open soon.
A veteran-founded nonprofit that funds and coordinates psychedelic therapy, mostly ayahuasca and psilocybin retreats, for combat veterans carrying PTSD, depression, and moral injury. Well respected, well funded, and an obvious partner for this hub.
Founded by SEAL veteran Marcus Capone and his wife Amber after Marcus's own ibogaine treatment. VETS has paid for hundreds of veteran ibogaine and 5-MeO-DMT treatments, and its advocacy was central to getting the Texas $50M initiative off the ground. A direct line into both the policy and treatment worlds.
A focused clinical program led by Dr. Martín Polanco, combining ibogaine and 5-MeO-DMT therapy for special-operations veterans with TBI and PTSD. It's the clinical heart of the protocol Stanford studied, and a featured partner for this hub.
The most-followed pure-play psilocybin developer. Voucher recipient. Phase 3 readouts the single largest known-near-term catalyst in the publicly traded psychedelic space.
A platform-model holding company across multiple psychedelic and adjacent CNS programs — DMT, ibogaine derivatives, ketamine, and more. The diversified bet on the category.
The most clinically advanced LSD program in the regulated pipeline. MM-120 has put up strong Phase 2 numbers in generalized anxiety disorder. The lysergic torch, carried forward.
A deuterated psilocin program — pharmacologically optimized for shorter duration, more predictable PK, and an outpatient-friendly profile. The "if it can be psilocybin but two hours instead of six" thesis.
The first regulated 5-MeO-DMT program: inhaled, short-acting, with strong early efficacy data in TRD. The most chemically unusual public name in the bunch.
The voucher recipient with no shareholders. Usona's nonprofit structure is itself a piece of industry analysis — the answer to "who decides the price of psilocybin once it's approved" looks different when one of the approvers is a 501(c)(3).
Whatever path you take, clinical or ceremonial or somewhere in between, the one thing you really control is knowing what's actually in your substance. Reagent kits and fentanyl strips have been the through-line of harm reduction from Volume I right up to now.
DanceSafe · Test Kits & Reagents →